Business
Denali Therapeutics Inc. (NASDAQ:DNLI) has received an average rating of “Buy” from a group of seventeen analysts currently covering the company, according to MarketBeat....
Hi, what are you looking for?
AHECBLOG
- Top Stories
Charlie Sheen, 60, Dating Younger Man, Sources Confirm
Staten Island Ferry Collision: 11 Lives Lost on October 15, 2003
Nina Dobrev Sparks Frenzy with Stunning New Bikini Photo
Selena Gomez’s Friendship with Brooklyn Beckham Evolving, No Feud
Emotional “Dedication Night” Delivers Surprises on ‘Dancing with the Stars’
- World
- Politics
Reflecting on October 15: #MeToo Movement’s Viral Impact
NATO Ministers Gather to Strengthen Defenses Against Russia
Virginia Lee Thacker Velasco Bishop, 90, Remembered in Williamsburg
Indiana House Republicans Launch Paid Internships for 2026 Session
Walt Disney Stock Receives $131 Price Target from Analysts
- Business
Analysts Set Denali Therapeutics Price Target at $33.50
Linglong Tire Celebrates 50 Years with Global Partners in Madrid
U.S. Signs $20 Billion Currency Swap with Argentina Amid Financial Crisis
BGL Completes Sale of Garden State Medical Center Portfolio
Northwest Capital Management Reduces Stake in iShares Bond ETF
- Sports
Handel and Haydn Society’s “Saul” Captivates Boston Audience
Eichel’s Two Goals Propel Golden Knights to Victory Over Flames
Sterling Heights Stevenson Upsets Cousino to Reach Finals
Toews Returns with Assist as Jets Defeat Islanders 5-2
Rich Eisen Discusses Tua Tagovailoa’s Revelations on Dolphins’ Issues
- Technology
AI Solutions Transform Fleet Management and Road Safety
Elevate Your Editing: Personalization Options for Creators
Polaris Spins Off Indian Motorcycle, Sells Majority Stake to Carolwood
Irys Insurtech Secures $12.5 Million to Transform Insurance Software
Digital Onboarding Revolution: eKYC Systems Transform Identity Verification
- Health
Experiencing Blood Sugar Changes: One Month with a Monitor
Genetic Testing Empowers Women to Combat Breast Cancer Risks
Cleveland Joins National Prescription Drug Take Back Day on Oct. 25
Supreme Court Declines to Review FDA’s Stem Cell Authority Case
Streamlining the Diagnostic Process for Diffuse Midline Glioma
- Science
Oceanic Manta Rays Dive Deep for Navigation Insights
NYUAD Develops SPIRAL Implant for Precision Drug Delivery in Brain
Nokia Bell Labs Celebrates 100 Years with New Headquarters in N.J.
New Technologies and Trials Reshape Diabetes Care Landscape
New AI Framework Themeda Revolutionizes Land Cover Prediction
All posts tagged "TD Cowen"
Business
PVH Corp. (NYSE: PVH) has garnered a consensus recommendation of “Moderate Buy” from analysts, according to MarketBeat Ratings. This assessment comes from a review...
